Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection
Authors:
- 17 July 2014
- journal article
- review article
- Published by Wolters Kluwer Health in AIDS
- Vol. 28 (11) , 1545-1554
Abstract
Postexposure prophylaxis (PEP) with antiretroviral medication has been used as an HIV-prevention strategy for nearly 20 years. The fact that approximately 50 000 new HIV infections occur in the United States each year reflects marked underutilization of nonoccupational PEP (NPEP). There have been several advances in NPEP in the past 10 years. Clinical trials from different countries have demonstrated better tolerability, completion rates, and fewer drug–drug interactions with newer antiretroviral agents. Notably, there has been a shift from zidovudine-based to tenofovir-based regimens. Three-drug therapy is now favored for all potential HIV exposures. More recently, the US Public Health Service and the New York State Department of Health recommended tenofovir/emtricitabine and raltegravir as the first-line regimen universally for PEP. Advances in HIV testing technology may also allow shorter duration of follow-up HIV testing after a high-risk exposure. This review will discuss challenges with previously recommended regimens, newer potential candidate agents and the rationale for using them, intervals for laboratory monitoring, and cost considerations for NPEP. NPEP can be viewed as an educable moment and a potential bridge to preexposure prophylaxis, as part of a combination prevention package, for those who are likely to have recurrent higher-risk exposures. Thus, risk-reduction counseling should be an integral aspect of NPEP.Keywords
This publication has 71 references indexed in Scilit:
- Improved awareness and appropriate use of non-occupational post-exposure prophylaxis (nPEP) for HIV prevention following a multi-modal communication strategyBMC Public Health, 2012
- Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected PatientsAntimicrobial Agents and Chemotherapy, 2012
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA ComplexesAntimicrobial Agents and Chemotherapy, 2011
- The higher barrier of darunavir and tipranavir resistance for HIV-1 proteaseBiochemical and Biophysical Research Communications, 2011
- Factors Influencing the Emergence and Spread of HIV Drug Resistance Arising from Rollout of Antiretroviral Pre-Exposure Prophylaxis (PrEP)PLOS ONE, 2011
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase InhibitorAntimicrobial Agents and Chemotherapy, 2011
- Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or MonotherapyAntimicrobial Agents and Chemotherapy, 2010
- Pre‐existing Minority Drug‐Resistant HIV‐1 Variants, Adherence, and Risk of Antiretroviral Treatment FailureThe Journal of Infectious Diseases, 2010
- Alternative Algorithms for Human Immunodeficiency Virus Infection Diagnosis Using Tests That Are Licensed in the United StatesJournal of Clinical Microbiology, 2008
- Assessment of Rapid Tests for Detection of Human Immunodeficiency Virus-Specific Antibodies in Recently Infected IndividualsJournal of Clinical Microbiology, 2008